Sarepta's Setback Deepens With Another Gene Therapy Fatality
1. SRPT shares fell sharply following a third patient death this year. 2. The deceased was part of a trial for SRP-9004, showing acute liver failure. 3. FDA requested a black box warning for liver injury related to SRPT therapies. 4. Sarepta plans to deprioritize certain gene therapy developments post-deaths. 5. Analysts express concerns about overall investor confidence and safety of therapies.